Free Trial

Aureus Asset Management LLC Acquires 29,017 Shares of Chemed Co. (NYSE:CHE)

Chemed logo with Medical background

Aureus Asset Management LLC lifted its stake in Chemed Co. (NYSE:CHE - Free Report) by 3,147.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 29,939 shares of the company's stock after purchasing an additional 29,017 shares during the quarter. Aureus Asset Management LLC owned 0.20% of Chemed worth $17,993,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of CHE. Cetera Advisors LLC purchased a new position in Chemed during the 1st quarter valued at about $267,000. GAMMA Investing LLC grew its stake in Chemed by 34.4% in the 2nd quarter. GAMMA Investing LLC now owns 86 shares of the company's stock valued at $47,000 after buying an additional 22 shares during the last quarter. Mather Group LLC. increased its stake in shares of Chemed by 60.5% in the second quarter. Mather Group LLC. now owns 183 shares of the company's stock worth $99,000 after purchasing an additional 69 shares during the period. Harbor Capital Advisors Inc. boosted its holdings in Chemed by 292.7% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 1,241 shares of the company's stock valued at $673,000 after purchasing an additional 925 shares during the period. Finally, CWM LLC increased its position in shares of Chemed by 18.5% during the second quarter. CWM LLC now owns 397 shares of the company's stock valued at $215,000 after purchasing an additional 62 shares during the period. Institutional investors and hedge funds own 95.85% of the company's stock.

Chemed Stock Down 1.0 %

CHE stock traded down $5.96 during midday trading on Monday, reaching $566.43. The company's stock had a trading volume of 80,013 shares, compared to its average volume of 85,833. The business's 50-day simple moving average is $578.27 and its 200-day simple moving average is $565.05. Chemed Co. has a 52 week low of $523.33 and a 52 week high of $654.62. The stock has a market cap of $8.52 billion, a PE ratio of 28.84, a price-to-earnings-growth ratio of 2.43 and a beta of 0.46.

Chemed (NYSE:CHE - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $5.64 earnings per share for the quarter, missing analysts' consensus estimates of $5.76 by ($0.12). The firm had revenue of $606.18 million during the quarter, compared to analyst estimates of $612.22 million. Chemed had a net margin of 12.69% and a return on equity of 27.86%. The business's revenue was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.32 earnings per share. As a group, equities analysts forecast that Chemed Co. will post 21.43 earnings per share for the current fiscal year.

Chemed Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 6th. Shareholders of record on Monday, November 18th will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 0.35%. The ex-dividend date is Monday, November 18th. Chemed's dividend payout ratio (DPR) is presently 10.11%.

Insider Buying and Selling at Chemed

In other news, EVP Spencer S. Lee sold 732 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $575.62, for a total transaction of $421,353.84. Following the sale, the executive vice president now owns 18,287 shares in the company, valued at $10,526,362.94. This represents a 3.85 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director George J. Walsh III sold 400 shares of the stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $597.47, for a total transaction of $238,988.00. Following the completion of the sale, the director now owns 3,046 shares of the company's stock, valued at approximately $1,819,893.62. This represents a 11.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,845 shares of company stock valued at $3,978,798 in the last 90 days. 3.32% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on CHE shares. StockNews.com upgraded shares of Chemed from a "hold" rating to a "buy" rating in a research note on Saturday. Royal Bank of Canada cut their price objective on Chemed from $697.00 to $633.00 and set an "outperform" rating for the company in a report on Tuesday, November 5th.

Check Out Our Latest Research Report on Chemed

Chemed Profile

(Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

See Also

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Should you invest $1,000 in Chemed right now?

Before you consider Chemed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.

While Chemed currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines